Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Clinical factors associated with urinary tract cancer in individuals with Lynch syndrome.

Wischhusen JW, Ukaegbu C, Dhingra TG, Uno H, Kastrinos F, Syngal S, Yurgelun MB.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 15. pii: cebp.0213.2019. doi: 10.1158/1055-9965.EPI-19-0213. [Epub ahead of print]

PMID:
31615790
2.

Health behaviours and beliefs in individuals with familial pancreatic cancer.

Underhill-Blazey M, Blonquist T, Lawrence J, Hong F, Yurgelun MB, Syngal S.

Fam Cancer. 2019 Oct;18(4):457-464. doi: 10.1007/s10689-019-00143-7.

3.

Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome.

Kim J, Braun D, Ukaegbu C, Dhingra TG, Kastrinos F, Parmigiani G, Syngal S, Yurgelun MB.

Clin Gastroenterol Hepatol. 2019 Jul 15. pii: S1542-3565(19)30745-1. doi: 10.1016/j.cgh.2019.07.012. [Epub ahead of print]

PMID:
31319185
4.

Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers.

Christakis AG, Papke DJ, Nowak JA, Yurgelun MB, Agoston AT, Lindeman NI, MacConaill LE, Sholl LM, Dong F.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1246-1251. doi: 10.1158/1055-9965.EPI-18-1250. Epub 2019 Apr 26.

PMID:
31028081
5.

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.

Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS.

JAMA. 2019 Apr 9;321(14):1370-1379. doi: 10.1001/jama.2019.2402.

6.

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32029. [Epub ahead of print]

PMID:
30913304
7.

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.

Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM.

Br J Cancer. 2019 Apr;120(8):848-854. doi: 10.1038/s41416-019-0426-5. Epub 2019 Mar 14.

PMID:
30867564
8.

Multigene panel testing versus syndrome-specific germline testing for inherited cancer risk: 'a somewhat different way'.

Biller LH, Yurgelun MB.

Per Med. 2019 Mar;16(2):83-86. doi: 10.2217/pme-2018-0109. Epub 2019 Feb 11. No abstract available.

PMID:
30741585
9.

Genetics of Familial and Sporadic Pancreatic Cancer.

Wood LD, Yurgelun MB, Goggins MG.

Gastroenterology. 2019 May;156(7):2041-2055. doi: 10.1053/j.gastro.2018.12.039. Epub 2019 Jan 18. Review.

PMID:
30660730
10.

Recent advances in Lynch syndrome.

Biller LH, Syngal S, Yurgelun MB.

Fam Cancer. 2019 Apr;18(2):211-219. doi: 10.1007/s10689-018-00117-1. Review.

PMID:
30627969
11.

Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights Into an Old Diagnostic Strategy.

Yurgelun MB, Kastrinos F.

J Clin Oncol. 2019 Feb 1;37(4):263-265. doi: 10.1200/JCO.18.01664. Epub 2018 Dec 14. No abstract available.

PMID:
30550362
12.

Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention.

Yurgelun MB, Hampel H.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:101-109. doi: 10.1200/EDBK_208341. Review.

PMID:
30231390
13.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

14.

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.

Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.

Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.

15.

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Papke DJ Jr, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, Sholl LM, MacConaill LE, Dong F.

Mod Pathol. 2018 Dec;31(12):1882-1890. doi: 10.1038/s41379-018-0091-x. Epub 2018 Jun 28.

PMID:
29955144
16.

Precision Prevention and Early Detection of Cancer: Fundamental Principles.

Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G, Schrag D, Syngal S, Tamimi RM, Viswanath K, Yurgelun MB, Garber JE.

Cancer Discov. 2018 Jul;8(7):803-811. doi: 10.1158/2159-8290.CD-17-1415. Epub 2018 Jun 15.

17.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

18.

A counseling framework for moderate-penetrance colorectal cancer susceptibility genes.

Katona BW, Yurgelun MB, Garber JE, Offit K, Domchek SM, Robson ME, Stadler ZK.

Genet Med. 2018 Nov;20(11):1324-1327. doi: 10.1038/gim.2018.12. Epub 2018 Mar 1. No abstract available.

PMID:
29493579
19.

Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.

Boland PM, Yurgelun MB, Boland CR.

CA Cancer J Clin. 2018 May;68(3):217-231. doi: 10.3322/caac.21448. Epub 2018 Feb 27. Review.

20.

Inherited DNA-Repair Defects in Colorectal Cancer.

AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, Mu XJ, Nishihara R, Qian Z, Liu L, Yurgelun MB, Syngal S, Garraway LA, Ogino S, Fuchs CS, Van Allen EM.

Am J Hum Genet. 2018 Mar 1;102(3):401-414. doi: 10.1016/j.ajhg.2018.01.018. Epub 2018 Feb 22.

21.

The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration.

Giri VN, Yurgelun MB, Robson ME.

Ann Intern Med. 2017 Dec 19;167(12):884-885. doi: 10.7326/M17-2512. Epub 2017 Oct 31. No abstract available.

PMID:
29086794
22.

Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net.

Yurgelun MB.

J Clin Oncol. 2017 Oct 20;35(30):3375-3377. doi: 10.1200/JCO.2017.74.7535. Epub 2017 Aug 23. No abstract available.

PMID:
28834438
23.

Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome.

Luba DG, DiSario JA, Rock C, Saraiya D, Moyes K, Brown K, Rushton K, Ogara MM, Raphael M, Zimmerman D, Garrido K, Silguero E, Nelson J, Yurgelun MB, Kastrinos F, Wenstrup RJ, Syngal S.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):49-58. doi: 10.1016/j.cgh.2017.06.038. Epub 2017 Jun 28.

24.

Mutational cascades in cancer.

Boland CR, Yurgelun MB.

Oncotarget. 2017 Jun 27;8(26):41784-41785. doi: 10.18632/oncotarget.18481. No abstract available.

25.

Reply to M.S. Daniels et al.

Yurgelun MB, Syngal S.

J Clin Oncol. 2017 Aug 1;35(22):2588-2589. doi: 10.1200/JCO.2017.73.3840. Epub 2017 May 16. No abstract available.

PMID:
28510494
26.

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S.

J Clin Oncol. 2017 Jul 1;35(19):2165-2172. doi: 10.1200/JCO.2016.69.6120. Epub 2017 May 10.

27.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

28.

Historical Perspective on Familial Gastric Cancer.

Boland CR, Yurgelun MB.

Cell Mol Gastroenterol Hepatol. 2017 Feb 28;3(2):192-200. doi: 10.1016/j.jcmgh.2016.12.003. eCollection 2017 Mar. Review.

29.

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX.

Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13.

30.

Translating Germline Cancer Risk into Precision Prevention.

Yurgelun MB, Chenevix-Trench G, Lippman SM.

Cell. 2017 Feb 9;168(4):566-570. doi: 10.1016/j.cell.2017.01.031.

31.

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S.

J Clin Oncol. 2017 Apr 1;35(10):1086-1095. doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30.

32.

Genetic predisposition to colorectal cancer: Implications for treatment and prevention.

Stoffel EM, Yurgelun MB.

Semin Oncol. 2016 Oct;43(5):536-542. doi: 10.1053/j.seminoncol.2016.08.002. Epub 2016 Sep 1. Review.

PMID:
27899184
33.

"New" Cancer Genes and Inherited Colorectal Cancer Risk: Caveat Emptor.

Yurgelun MB, Boland CR.

Gastroenterology. 2017 Jan;152(1):12-13. doi: 10.1053/j.gastro.2016.11.027. Epub 2016 Nov 23. No abstract available.

PMID:
27889571
34.

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.

Nowak JA, Yurgelun MB, Bruce JL, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, Agoston AT, Srivastava A, Ogino S, Kuo FC, Lindeman NI, Dong F.

J Mol Diagn. 2017 Jan;19(1):84-91. doi: 10.1016/j.jmoldx.2016.07.010. Epub 2016 Nov 15.

35.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

36.

Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome.

Watkins JC, Yang EJ, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Syngal S, Yurgelun MB, Chittenden A, Hornick JL, Crum CP, Sholl LM, Howitt BE.

Int J Gynecol Pathol. 2017 Mar;36(2):115-127. doi: 10.1097/PGP.0000000000000312.

PMID:
27556954
37.

Advances in Hereditary Colorectal and Pancreatic Cancers.

Underhill ML, Germansky KA, Yurgelun MB.

Clin Ther. 2016 Jul;38(7):1600-21. doi: 10.1016/j.clinthera.2016.03.017. Epub 2016 Apr 2. Review.

38.

Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?

Yurgelun MB, Hiller E, Garber JE.

J Clin Oncol. 2015 Oct 1;33(28):3092-5. doi: 10.1200/JCO.2015.60.8596. Epub 2015 Aug 17. No abstract available.

PMID:
26282646
39.

Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.

Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, Hopper JL, Jenkins MA, Buchanan DD, Newcomb PA, Potter JD, Haile RW, Kucherlapati R, Syngal S; Colon Cancer Family Registry.

JAMA Oncol. 2015 May;1(2):214-21.

40.

Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.

Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S.

Gastroenterology. 2015 Sep;149(3):604-13.e20. doi: 10.1053/j.gastro.2015.05.006. Epub 2015 May 14.

41.

Next-generation strategies for hereditary colorectal cancer risk assessment.

Yurgelun MB.

J Clin Oncol. 2015 Feb 10;33(5):388-93. doi: 10.1200/JCO.2014.58.9895. Epub 2015 Jan 5. No abstract available.

PMID:
25559814
42.

Therapy-associated polyposis as a late sequela of cancer treatment.

Yurgelun MB, Hornick JL, Curry VK, Ukaegbu CI, Brown EK, Hiller E, Chittenden A, Goldberg JE, Syngal S.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1046-50. doi: 10.1016/j.cgh.2013.11.040. Epub 2013 Dec 19.

43.

Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.

Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM.

Gynecol Oncol. 2012 Dec;127(3):544-51. doi: 10.1016/j.ygyno.2012.08.031. Epub 2012 Aug 29.

44.

Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps.

Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, Ruffin MT 4th, Marcon NE, Baron JA, Bresalier RS, Syngal S, Brenner DE, Boland CR, Stoffel EM.

Cancer Prev Res (Phila). 2012 Apr;5(4):574-82. doi: 10.1158/1940-6207.CAPR-11-0519. Epub 2012 Jan 18.

45.

Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone.

Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY.

J Orthop Res. 2005 Jan;23(1):203-9.

Supplemental Content

Loading ...
Support Center